Anti-Respiratory Syncytial Virus (RSV)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

This monoclonal antibody is purified from ascites fluid or culture medium by protein A chromatography or sequential differential precipitations.

This product contains no stabilizing proteins and should be stored at 2-8°C until ready to use. This clone is non-reactive with: Influenza A & B, Adenovirus, Para 1-3, Measles, Mumps

Ships Overnight on Blue Ice

Respiratory Syncytial Virus (Clone RSV-210915) is specific for the fusion protein of RSV Types A&B.

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the majority of children by two years old^{1, 2}. While usually mild, RSV can be serious in infants and older adults and is the leading cause of bronchiolitis and pneumonia in children less than one year of age in the United States¹. A related pneumovirus, human metapneumovirus (hMPV), also significantly contributes to hospitalizations resulting from lower respiratory tract infection². Antibodies have been described that bind and neutralize both RSV and hMPV fusion (F) proteins.

RSV F protein is a type I integral membrane protein that is synthesized as a 574 amino acid inactive precursor, assembled into a trimer, post-translationally modified, then cleaved to produce F1, F2, and intervening peptide pep273. Functional F protein has both pre- and post-fusion conformations. RSV F protein is highly conserved among RSV isolates from both A and B subgroups³ and is the primary target for antiviral drug development³ with several antigenic regions capable of introducing neutralizing antibodies². RSV and hMPV F protein share ~36% sequence similarity.

1. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, Link Text
2. Mousa JJ, Binshtein E, Human S, et al. PLoS Pathog. 14(2):e1006837. 2018.
3. McLellan JS, Ray WC, Peeples ME. Curr Top Microbiol Immunol. 372:83-104. 2013.